{"url_path":"/sec/aptof/8-k/2026-07-01/item-3-03","section_key":"item-3-03","section_title":"Item 3.03 Material Modifications to Rights of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/882361/0001193125-26-291114-index.html","accession_number":"0001193125-26-291114","cik":"0000882361","ticker":"APTOF","issuer_name":"Aptose Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/882361/0001193125-26-291114-index.html","primary_entity_key":"0000882361","primary_entity_name":"Aptose Biosciences Inc."},"word_count":140,"has_tables":true,"body_markdown":"Item 3.03\n\nMaterial Modifications to Rights of Security Holders.\n\nAs set forth under Item 2.01 of this Current Report on Form 8-K, at the Effective Time, each Common Share issued and outstanding immediately prior to the Effective Time, other than Common Shares beneficially owned or controlled by Parent or any of its affiliates, was converted into the right to receive C$2.41 in cash, subject to applicable withholdings and other source deductions (the “Arrangement Consideration”). At the Effective Time, all holders of Common Shares (other than Common Shares beneficially owned or controlled by Parent or any of its affiliates) ceased to have any rights with respect thereto other than the right to receive the Arrangement Consideration.\n\nThe information set forth under Items 2.01, 5.01 and 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03."}